CJ
PCRX icon

Caitlin John’s Pacira BioSciences PCRX Stock Holding History

Caitlin John’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Buy
4,721
+337
+8% +$7.97K 0.07% 246
2026
Q1 		$99.1K Buy
4,384
+180
+4% +$4K 0.06% 229
2025
Q4 		$109K Sell
4,204
-1
-0% -$24 0.07% 223
2025
Q3 		$108K Buy
+4,205
New +$103K 0.08% 178
2025
Q1 		– Sell
-1,872
Closed -$35.3K – 599
2024
Q4 		$35.3K Buy
1,872
+1,776
+1,850% +$31.2K 0.02% 282
2024
Q3 		$1.58K Hold
96
– – ﹤0.01% 683
2024
Q2 		$2.75K Hold
96
– – ﹤0.01% 618
2024
Q1 		$2.81K Sell
96
-8
-8% -$246 ﹤0.01% 642
2023
Q4 		$3.51K Buy
+104
New +$3.04K ﹤0.01% 616

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caitlin John's PCRX Position: Q2 2026 in Review

Caitlin John increased its Pacira BioSciences (PCRX) stake by 7.7% in Q2 2026, buying an estimated $7.97K and bringing the position to 4,721 shares worth $120K. The position accounts for 0.07% of the portfolio, ranked #246.

Caitlin John first reported a position in PCRX in Q4 2023 and has held it in 9 quarters since. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Caitlin John held 4,721 shares of Pacira BioSciences worth $120K as of Q2 2026.
  • Caitlin John bought 337 Pacira BioSciences shares in Q2 2026, an estimated $7.97K.
  • Pacira BioSciences made up 0.07% of Caitlin John's portfolio in Q2 2026, its #246 holding.
  • Caitlin John first reported a position in Pacira BioSciences in Q4 2023 and has held it in 9 quarters since.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Caitlin John's 13F filing for Q2 2026, filed 17 Aug 2026.